3 research outputs found
Relative resistance of HIV-1 founder viruses to control by interferon-alpha
Background: Following mucosal human immunodeficiency virus type 1 (HIV-1) transmission, type 1 interferons
(IFNs) are rapidly induced at sites of initial virus replication in the mucosa and draining lymph nodes. However, the
role played by IFN-stimulated antiviral activity in restricting HIV-1 replication during the initial stages of infection is
not clear. We hypothesized that if type 1 IFNs exert selective pressure on HIV-1 replication in the earliest stages of
infection, the founder viruses that succeed in establishing systemic infection would be more IFN-resistant than viruses
replicating during chronic infection, when type 1 IFNs are produced at much lower levels. To address this hypothesis,
the relative resistance of virus isolates derived from HIV-1-infected individuals during acute and chronic infection to
control by type 1 IFNs was analysed.
Results: The replication of plasma virus isolates generated from subjects acutely infected with HIV-1 and molecularly
cloned founder HIV-1 strains could be reduced but not fully suppressed by type 1 IFNs in vitro. The mean IC50 value for
IFNα2 (22 U/ml) was lower than that for IFNβ (346 U/ml), although at maximally-inhibitory concentrations both IFN subtypes
inhibited virus replication to similar extents. Individual virus isolates exhibited differential susceptibility to inhibition by IFNα2
and IFNβ, likely reflecting variation in resistance to differentially up-regulated IFN-stimulated genes. Virus isolates
from subjects acutely infected with HIV-1 were significantly more resistant to in vitro control by IFNα than virus
isolates generated from the same individuals during chronic, asymptomatic infection. Viral IFN resistance declined
rapidly after the acute phase of infection: in five subjects, viruses derived from six-month consensus molecular clones
were significantly more sensitive to the antiviral effects of IFNs than the corresponding founder viruses.
Conclusions: The establishment of systemic HIV-1 infection by relatively IFNα-resistant founder viruses lends strong
support to the hypothesis that IFNα plays an important role in the control of HIV-1 replication during the earliest stages
of infection, prior to systemic viral spread. These findings suggest that it may be possible to harness the antiviral activity
of type 1 IFNs in prophylactic and potentially also therapeutic strategies to combat HIV-1 infection
The Promiscuous CC Chemokine Receptor D6 Is a Functional Coreceptor for Primary Isolates of Human Immunodeficiency Virus Type 1 (HIV-1) and HIV-2 on Astrocytes
The role of coreceptors other than CCR5 and CXCR4 in the pathogenesis of human immunodeficiency virus (HIV) disease is controversial. Here we show that a promiscuous CC chemokine receptor, D6, can function as a coreceptor for various primary dual-tropic isolates of HIV type 1 (HIV-1) and HIV-2. Furthermore, D6 usage is common among chimeric HIV-1 constructs bearing the gp120 proteins of isolates from early seroconverting patients. D6 mRNA and immunoreactivity were demonstrated to be expressed in HIV-1 target cells such as macrophages, peripheral blood mononuclear cells, and primary astrocytes. In primary astrocytes, an RNA interference-mediated knockdown of D6 expression inhibited D6-tropic isolate infection. D6 usage may account for some previous observations of alternative receptor tropism for primary human cells. Thus, D6 may be an important receptor for HIV pathogenesis in the brain and for the early dissemination of virus in the host
Recommended from our members
Mapping the immune response to the outer domain of a human immunodeficiency virus-1 clade C gp120
The outer domain (OD) of human immunodeficiency virus (HIV)-1 gp120 represents an attractive, if difficult, target for a beneficial immune response to HIV infection. Unlike the entire gp120, the OD is structurally stable and contains the surfaces that interact with both the primary and secondary cellular receptors. The primary strain-specific neutralizing target, the V3 loop, lies within the OD, as do epitopes for two cross-reactive neutralizing monoclonal antibodies (mAbs), b12 and 2G12, and the contact sites for a number of inhibitory lectins. The OD is poorly immunogenic, at least in the context of complete gp120, but purposeful OD immunization can lead to a substantial antibody response. Here, we map the antibody generated following immunization with a clade C OD. In contrast to published data for the clade B OD, the majority of the polyclonal response to the complete clade C OD is to the V3 loop; deletion of the loop substantially reduces immunogenicity. When the loop sequence was substituted for the epitope for 2F5, a well-characterized human cross-neutralizing mAb, a polyclonal response to the epitope was generated. A panel of mAbs against the clade C OD identified two mAbs that reacted with the loop and were neutralizing for clade C but not B isolates. Other mAbs recognized both linear and conformational epitopes in the OD. We conclude that, as for complete gp120, V3 immunodominance is a property of OD immunogens, that the responses can be neutralizing and that it could be exploited for the presentation of other epitopes